Hepatitis C-HIV coinfection

Current and future therapy

Jagdeep J. Vyas, Robert S. Brown, Paul J. Gaglio

Research output: Contribution to journalArticle

Abstract

Coinfection with hepatitis C in HIV-infected patients has been reported in 15-70% of patients depending on the mode of acquisition of both viruses. As recent advances in HIV-directed antiviral therapy have markedly delayed HIV progression and mortality, the incidence of complications arising from hepatitis C-associated liver disease in coinfected patients is increasing exponentially. The interaction of HIV and hepatitis C is complex. It is clear that HIV infection negatively affects the natural history of hepatitis C, while HIV-directed therapy may enhance immunologic response and exacerbate hepatocellular injury induced by hepatitis C via immune reconstitution. In this review, the pathobiology, inter-relation of hepatitis C and HIV infection in coinfected patients as well as present and future treatment in this unique patient population are discussed.

Original languageEnglish (US)
Pages (from-to)433-439
Number of pages7
JournalExpert Review of Anti-Infective Therapy
Volume1
Issue number3
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Hepatitis C
Coinfection
HIV
HIV Infections
Therapeutics
Antiviral Agents
Liver Diseases
Viruses
Mortality
Incidence
Wounds and Injuries
Population

Keywords

  • Helicase
  • Hepatitis C
  • HIV interferon
  • Isomerase
  • Pegylated interferon
  • Protease
  • Replicase
  • Ribavirin
  • Sustained virologic response

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology

Cite this

Vyas, J. J., Brown, R. S., & Gaglio, P. J. (2003). Hepatitis C-HIV coinfection: Current and future therapy. Expert Review of Anti-Infective Therapy, 1(3), 433-439.

Hepatitis C-HIV coinfection : Current and future therapy. / Vyas, Jagdeep J.; Brown, Robert S.; Gaglio, Paul J.

In: Expert Review of Anti-Infective Therapy, Vol. 1, No. 3, 10.2003, p. 433-439.

Research output: Contribution to journalArticle

Vyas, JJ, Brown, RS & Gaglio, PJ 2003, 'Hepatitis C-HIV coinfection: Current and future therapy', Expert Review of Anti-Infective Therapy, vol. 1, no. 3, pp. 433-439.
Vyas, Jagdeep J. ; Brown, Robert S. ; Gaglio, Paul J. / Hepatitis C-HIV coinfection : Current and future therapy. In: Expert Review of Anti-Infective Therapy. 2003 ; Vol. 1, No. 3. pp. 433-439.
@article{7dd2cce80a4d426699bd5cf7bc5cbdef,
title = "Hepatitis C-HIV coinfection: Current and future therapy",
abstract = "Coinfection with hepatitis C in HIV-infected patients has been reported in 15-70{\%} of patients depending on the mode of acquisition of both viruses. As recent advances in HIV-directed antiviral therapy have markedly delayed HIV progression and mortality, the incidence of complications arising from hepatitis C-associated liver disease in coinfected patients is increasing exponentially. The interaction of HIV and hepatitis C is complex. It is clear that HIV infection negatively affects the natural history of hepatitis C, while HIV-directed therapy may enhance immunologic response and exacerbate hepatocellular injury induced by hepatitis C via immune reconstitution. In this review, the pathobiology, inter-relation of hepatitis C and HIV infection in coinfected patients as well as present and future treatment in this unique patient population are discussed.",
keywords = "Helicase, Hepatitis C, HIV interferon, Isomerase, Pegylated interferon, Protease, Replicase, Ribavirin, Sustained virologic response",
author = "Vyas, {Jagdeep J.} and Brown, {Robert S.} and Gaglio, {Paul J.}",
year = "2003",
month = "10",
language = "English (US)",
volume = "1",
pages = "433--439",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Hepatitis C-HIV coinfection

T2 - Current and future therapy

AU - Vyas, Jagdeep J.

AU - Brown, Robert S.

AU - Gaglio, Paul J.

PY - 2003/10

Y1 - 2003/10

N2 - Coinfection with hepatitis C in HIV-infected patients has been reported in 15-70% of patients depending on the mode of acquisition of both viruses. As recent advances in HIV-directed antiviral therapy have markedly delayed HIV progression and mortality, the incidence of complications arising from hepatitis C-associated liver disease in coinfected patients is increasing exponentially. The interaction of HIV and hepatitis C is complex. It is clear that HIV infection negatively affects the natural history of hepatitis C, while HIV-directed therapy may enhance immunologic response and exacerbate hepatocellular injury induced by hepatitis C via immune reconstitution. In this review, the pathobiology, inter-relation of hepatitis C and HIV infection in coinfected patients as well as present and future treatment in this unique patient population are discussed.

AB - Coinfection with hepatitis C in HIV-infected patients has been reported in 15-70% of patients depending on the mode of acquisition of both viruses. As recent advances in HIV-directed antiviral therapy have markedly delayed HIV progression and mortality, the incidence of complications arising from hepatitis C-associated liver disease in coinfected patients is increasing exponentially. The interaction of HIV and hepatitis C is complex. It is clear that HIV infection negatively affects the natural history of hepatitis C, while HIV-directed therapy may enhance immunologic response and exacerbate hepatocellular injury induced by hepatitis C via immune reconstitution. In this review, the pathobiology, inter-relation of hepatitis C and HIV infection in coinfected patients as well as present and future treatment in this unique patient population are discussed.

KW - Helicase

KW - Hepatitis C

KW - HIV interferon

KW - Isomerase

KW - Pegylated interferon

KW - Protease

KW - Replicase

KW - Ribavirin

KW - Sustained virologic response

UR - http://www.scopus.com/inward/record.url?scp=3042785742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042785742&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 433

EP - 439

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 3

ER -